Cabot Stock Price, News & Analysis (NYSE:CBT)

Cabot trades on the New York Stock Exchange (NYSE) under the ticker symbol "CBT."

Cabot announced a quarterly dividend on Friday, July 12th. Investors of record on Friday, August 30th will be given a dividend of $0.35 per share on Friday, September 13th. This represents a $1.40 dividend on an annualized basis and a yield of 3.19%. The ex-dividend date is Thursday, August 29th. View Cabot's Dividend History.

Cabot announced that its board has approved a stock buyback plan on Monday, July 16th 2018, which authorizes the company to buyback $400,000,000.00 in shares, according to EventVestor. This buyback authorization authorizes the company to purchase up to 10.3% of its stock through open market purchases. Stock buyback plans are often an indication that the company's management believes its stock is undervalued.

Cabot Corp (NYSE:CBT) posted its quarterly earnings data on Monday, August, 5th. The specialty chemicals company reported $1.00 earnings per share for the quarter, hitting the consensus estimate of $1.00. The specialty chemicals company had revenue of $845 million for the quarter, compared to the consensus estimate of $858.86 million. Cabot had a return on equity of 18.60% and a net margin of 6.49%. The firm's quarterly revenue was down 1.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.06 earnings per share. View Cabot's Earnings History.

Cabot is scheduled to release their next quarterly earnings announcement on Monday, November 4th 2019. View Earnings Estimates for Cabot.

Cabot will be holding an earnings conference call on Monday, November 4th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

4 Wall Street analysts have issued 12 month price objectives for Cabot's stock. Their forecasts range from $40.00 to $45.00. On average, they anticipate Cabot's share price to reach $42.75 in the next twelve months. This suggests that the stock has a possible downside of 2.6%. View Analyst Price Targets for Cabot.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cabot in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cabot.

Media coverage about CBT stock has been trending negative on Wednesday, according to InfoTrie. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Cabot earned a media sentiment score of -2.4 on InfoTrie's scale. They also gave media stories about the specialty chemicals company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Cabot.

Cabot saw a decline in short interest in September. As of September 30th, there was short interest totalling 689,500 shares, a decline of 7.2% from the August 30th total of 743,000 shares. Based on an average daily volume of 339,500 shares, the days-to-cover ratio is presently 2.0 days. Approximately 1.2% of the company's stock are short sold. View Cabot's Current Options Chain.

Some companies that are related to Cabot include Versum Materials (VSM), Platform Specialty Products (PAH), WD-40 (WDFC), Element Solutions (ESI), Orion Engineered Carbons (OEC), Advanced Emissions Solutions (ADES), Flotek Industries (FTK), Pure Bioscience (PURE), HighCom Global Security (HCGS), GlyEco (GLYE), Artemis Therapeutics (ATMS) and Ener-Core (ENCR).

Based on aggregate information from My MarketBeat watchlists, some companies that other Cabot investors own include Broadcom (AVGO), JPMorgan Chase & Co. (JPM), Energy Transfer LP Unit (ET), Oracle (ORCL), Wells Fargo & Co (WFC), Adobe (ADBE), Gilead Sciences (GILD), AT&T (T), Micron Technology (MU) and Cisco Systems (CSCO).

Cabot's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Pacer Advisors Inc. (0.04%), Biltmore Wealth Management LLC (0.03%), State of Alaska Department of Revenue (0.02%), Ferguson Wellman Capital Management Inc. (0.01%) and North Star Investment Management Corp. (0.00%). Company insiders that own Cabot stock include Brian A Berube, Gottberg Friedrich Von, Hobart Kalkstein, James Patrick Kelly, Michael M Morrow, Nicholas S Cross, Patrick M Prevost and Sean D Keohane. View Institutional Ownership Trends for Cabot.

CBT stock was sold by a variety of institutional investors in the last quarter, including Pacer Advisors Inc.. View Insider Buying and Selling for Cabot.

CBT stock was acquired by a variety of institutional investors in the last quarter, including Biltmore Wealth Management LLC, Ferguson Wellman Capital Management Inc., State of Alaska Department of Revenue and North Star Investment Management Corp.. View Insider Buying and Selling for Cabot.

Shares of CBT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CBT stock can currently be purchased for approximately $43.87.

Cabot has a market capitalization of $2.53 billion and generates $3.24 billion in revenue each year. The specialty chemicals company earns $-113,000,000.00 in net income (profit) each year or $4.03 on an earnings per share basis. Cabot employs 4,600 workers across the globe.View Additional Information About Cabot.

The official website for Cabot is http://www.cabot-corp.com/.

Cabot's mailing address is TWO SEAPORT LANE SUITE 1300, BOSTON MA, 02210. The specialty chemicals company can be reached via phone at 617-345-0100 or via email at [email protected]